Lilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staff

PartnershipnegativeNegative

AI Analysis

Summary

Eli Lilly has terminated its collaboration with Foghorn Therapeutics on synthetic lethality drug development, leading Foghorn to reduce its workforce by 40%.

Outcome Details

Eli Lilly terminated collaboration with Foghorn Therapeutics on synthetic lethality drug development

Importance:6/10

Sentiment:

-0.85

partnership terminationheadcount reductiondrug developmentcollaborationsynthetic lethality

Related Companies

$LLY

Read the original article

Published by Endpoints News on October 1, 2026 2:14 PM

Read Original